Project Title

A Phase 1 Dose-Escalation and Expansion Study of BGB-16673 in Patients With B-Cell Malignancies

Official Title

A Phase 1, Open-Label, Dose-Escalation and -Expansion Study of the Bruton Tyrosine Kinase-Targeted Protein-Degrader BGB-16673 in Patients With B-Cell Malignancies

Project Summary

Study consists of two parts to explore BGB-16673 recommended dosing, a part 1 monotherapy dose finding and a part 2 (cohort expansion in two cohorts)

Blood Disorders

  • Marginal Zone Lymphoma

  • Follicular Lymphoma

  • Mantle Cell Lymphoma

  • Chronic Lymphocytic Leukaemia

  • Small Lymphocytic Leukaemia

  • Waldenstrom's Macroglobulinemia

Patient Recruitment Details

Patient recruitment status: Open

Number of Patients (Globally)